| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Ribapharm, Inc. |
| 3300 Hyland Avenue, Costa Mesa, CA 92626 * (714) 545-0100 |
| Business Description | The Company is a biotechnology company that seeks to discover, develop and commercialize innovative products for the treatment of significant unmet medical needs, principally in the antiviral and anticancer areas. |
|
Filing Information Not yet | ||||
| To Trade As | RIBA (NASNTL) | Industry | Pharmaceutical (SIC 2834) | |
| Type of Stock Offered | Class A Common Shares | Filing Date | 6/15/00 | |
| Domestic Shares Filed | 18,000,000 | Filing Range | $13.00 - $15.00 | |
| Foreign Shares Filed | 0 | Offering Amount | $252,000,000 | |
| Company Shares | 18,000,000 | Est. Expenses | - - | |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - | |
| Being spun off from | ICN Pharmaceuticals, Inc. | |||
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| UBS Warburg LLC | Lead Manager | |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 |
| Revenues | 0.354 | 1.753 | 3.223 | 36.830 | 109.592 | 16.208 | 34.272 |
| Income from Oper. | -9.793 | -11.089 | -13.464 | 19.908 | 98.461 | 14.130 | 31.612 |
| Net Income | -6.819 | -7.593 | -9.054 | 12.351 | 62.762 | 8.985 | 20.231 |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | 395.20 | 83.86 | 1,042.72 | 197.562 | 111.45 | ||
| Net Income Growth (%) | - | - | - | 408.15 | 125.16 | ||
| Oper. Profit Margin (%) | - | - | - | 54.05 | 89.84 | 92.24 | 87.18 |
| Net Profit Margin (%) | - | - | - | 33.54 | 57.27 | 59.03 | 55.44 |
| Cash Flow - Oper. | 7.68 | 0.13 | 0.03 | ||||
| Cash Flow - Inv. | -0.05 | -0.01 | -0.03 | ||||
| Cash Flow - Fin. | -7.63 | -0.12 | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 29.56 | Current Assets | 8.34 | Current Ratio | 5.74 |
| Total Liab. | 13.59 | Current Liab. | 1.45 | Debt Ratio | 45.98% |
| Total Equity | 15.97 | Working Cap. | 6.89 | Debt to Equity Ratio | 0.85 |
| Cash | - | Return on Assets | 68.44% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to prepay in full the outstanding note the Company issued to ICN as a dividend; to expand our research facilities and staff; to fund research and product development, including clinical trials; for potential acquisitions of product candidates, technologies and businesses that complement our business; and for general corporate purposes and working capital requirements. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Fried, Frank, Harris, Shriver & Jacobson |
| Bank's Law Firm | Dewey Ballantine |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| ICN Pharmaceuticals | 100.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||